Trial Profile

A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer; Meningeal carcinomatosis
Focus Therapeutic Use

04 Jun 2024 Results assessing additional data on LM objective response, provider-rated neurologic clinical exam, and patient-reported outcomes, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
07 Feb 2023 Planned End Date changed from 1 Sep 2023 to 22 Jul 2024.
19 Nov 2021 According to a Seagen media release, data from this study will be at the San Antonio Breast Cancer Symposium (SABCS), taking place December 7-10, 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com